Safe Oral Hypoglycemic Agents in CKD
For patients with type 2 diabetes and CKD, metformin and SGLT2 inhibitors are first-line therapy for eGFR ≥30 mL/min/1.73 m², with specific dose adjustments required as kidney function declines. 1
First-Line Therapy (eGFR ≥30 mL/min/1.73 m²)
Metformin
Metformin remains safe and recommended down to eGFR 30 mL/min/1.73 m² with appropriate dose adjustments. 1, 2
Dosing by eGFR:
- eGFR ≥60: Full dose (up to 2000-2550 mg/day)
- eGFR 45-59: Continue full dose initially; consider reducing to half dose in certain conditions
- eGFR 30-44: Reduce to half the maximum dose (initiate at half dose if starting new)
- eGFR <30: Discontinue metformin; do not initiate 1, 2
Monitoring requirements:
- eGFR ≥60: Monitor at least annually
- eGFR <60: Monitor every 3-6 months 1, 2
- Monitor vitamin B12 after 4+ years of use 2
SGLT2 Inhibitors
SGLT2 inhibitors are strongly recommended for eGFR ≥20-30 mL/min/1.73 m² for kidney and cardiovascular protection, even as glucose-lowering efficacy diminishes. 1, 3, 4
Key points:
- Initiate at eGFR ≥20-30 mL/min/1.73 m² (varies by agent)
- Continue even if eGFR falls below 30 mL/min/1.73 m² once started 1
- Prioritize agents with documented kidney/cardiovascular benefits (canagliflozin, dapagliflozin, empagliflozin) 1, 3
- Glucose-lowering efficacy reduced at eGFR <45 mL/min/1.73 m², but renal/cardiovascular benefits persist 3, 4
Agent-specific dosing (eGFR 30-44 mL/min/1.73 m²): 3
- Canagliflozin: Maximum 100 mg daily
- Dapagliflozin: 10 mg daily (can initiate down to eGFR 25)
- Empagliflozin: 10 mg daily (initiation not recommended <30 for glycemic control)
Additional Agents When Needed
GLP-1 Receptor Agonists
GLP-1 RAs are the preferred third-line agent after metformin and SGLT2i, particularly for advanced CKD. 2, 4
Advantages in CKD:
- No dose adjustment needed for most agents (dulaglutide, liraglutide, semaglutide) 5, 2, 3
- Preferred for eGFR <30 mL/min/1.73 m² due to low hypoglycemia risk 4
- Cardiovascular benefits demonstrated 3
Agent-specific considerations: 5, 2
- Dulaglutide, liraglutide, semaglutide (injectable/oral): No dose adjustment; limited data in severe CKD but generally safe
- Exenatide: Use only if eGFR >30-50 mL/min/1.73 m² (avoid extended-release if eGFR <45)
- Lixisenatide: Avoid if eGFR <15 mL/min/1.73 m²
DPP-4 Inhibitors
DPP-4 inhibitors are safe across all CKD stages but require dose adjustments for most agents. 5, 3
Dosing by eGFR 30-44 mL/min/1.73 m²: 5, 3
- Linagliptin: No adjustment needed (preferred in CKD)
- Sitagliptin: Reduce to 50 mg daily (25 mg if eGFR <30)
- Saxagliptin: Reduce to 2.5 mg daily if eGFR ≤45
- Alogliptin: Reduce to 12.5 mg daily (6.25 mg if eGFR <30)
Sulfonylureas
Use with extreme caution; high hypoglycemia risk in CKD. 5, 1
Safer options if needed:
- Glipizide: Hepatically metabolized; initiate conservatively at 2.5 mg daily 5
- Glimepiride: Start at 1 mg daily; titrate slowly 5, 3
- Glyburide: AVOID—contraindicated in CKD 5
Meglitinides
Repaglinide is the only meglitinide recommended in CKD. 5
- Initiate conservatively at 0.5 mg with meals if eGFR <30 mL/min/1.73 m²
- Lower hypoglycemia risk than sulfonylureas
Thiazolidinediones (TZDs)
Pioglitazone requires no dose adjustment but has significant adverse effects. 5, 3
- Risk of fluid retention and heart failure exacerbation
- Use cautiously; generally not preferred in CKD
Agents to AVOID in Advanced CKD
For eGFR <30 mL/min/1.73 m² or dialysis:
- Metformin: Contraindicated (lactic acidosis risk) 1
- Glyburide: Contraindicated (severe hypoglycemia risk) 5
- Acarbose/Miglitol: Not recommended if eGFR <25-30 mL/min/1.73 m² 3
Treatment Algorithm Summary
eGFR ≥30 mL/min/1.73 m²:
- Metformin (dose-adjusted) + SGLT2 inhibitor
- Add GLP-1 RA if glycemic targets not met
- Consider DPP-4 inhibitor (linagliptin preferred) or insulin if needed
eGFR <30 mL/min/1.73 m² or dialysis:
- Discontinue metformin
- Continue SGLT2 inhibitor if already on (for renal/CV protection)
- GLP-1 RA preferred for glycemic control 4
- Insulin as needed
- DPP-4 inhibitors (dose-adjusted) or repaglinide as alternatives
Critical Safety Considerations
Common pitfalls to avoid:
- Failing to discontinue metformin at eGFR <30 (lactic acidosis risk)
- Using glyburide in any stage of CKD
- Stopping SGLT2 inhibitors when eGFR drops below initiation threshold (continue for renal protection)
- Not reducing insulin doses by 25-50% in advanced CKD (increased hypoglycemia risk) 5
- Overlooking vitamin B12 monitoring with long-term metformin use
Monitor closely:
- eGFR every 3-6 months when <60 mL/min/1.73 m²
- Hypoglycemia risk increases substantially with declining kidney function
- Volume status when initiating SGLT2 inhibitors 1